Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView’s latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum